Search

Displaying results 4511 - 4520 of 6076 in total
  1. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.

  2. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  3. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

  4. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis.

  5. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) ...

  6. Drug

    Proglumide

    go.drugbank.com/drugs/DB13431
    Investigational

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  7. Drug

    Cefetamet

    go.drugbank.com/drugs/DB13504
    Investigational

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Propicillin

    go.drugbank.com/drugs/DB13660
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    MDX-1379

    go.drugbank.com/drugs/DB05329
    Investigational

    MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.

  10. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).